智通财经APP获悉，信达生物(01801)午前涨超3%，截至发稿，涨2.57%，报35.95港元，成交额1.46亿港元。
消息面上，12月16日，信达生物和礼来共同宣布，就礼来非共价(可逆)BTK抑制剂捷帕力(匹妥布替尼100毫克和50毫克片剂)在中国内地的权益达成以下合作协议：信达生物将负责捷帕力的进口、销售、推广和分销工作；礼来将负责捷帕力的研发和上市后医学事务相关工作。
美银证券研报指出，信达生物与礼来就后者的非共价(可逆)BTK抑制剂“捷帕力”达成中国内地商业化协议，将该产品的销售预测计算在内后，相应将公司2025及2026年收入预测分别上调1.9%及3.4%，目标价从54.1港元上调至56.4港元，重申“买入”评级。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.